Holen Sie sich die Stockscreener-App
81.14
2.66%
-2.22
Handel nachbörslich:
81.02
-0.12
-0.15%
Schlusskurs vom Vortag:
$83.36
Offen:
$83.93
24-Stunden-Volumen:
2.32M
Relative Volume:
2.11
Marktkapitalisierung:
$4.31B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.99M
KGV:
-27.08
EPS:
-2.9966
Netto-Cashflow:
$-24.94M
1W Leistung:
-0.06%
1M Leistung:
-0.52%
6M Leistung:
+58.08%
1J Leistung:
+63.85%
1-Tages-Spanne:
$80.97
$84.19
1-Wochen-Bereich:
$77.33
$87.17
52-Wochen-Spanne:
$41.50
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Firmenname
Soleno Therapeutics Inc
Sektor
Branche
Telefon
650-213-8444
Adresse
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Vergleichen Sie SLNO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
81.14 | 4.43B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-23 | Eingeleitet | TD Cowen | Buy |
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2024-12-02 | Bestätigt | Robert W. Baird | Outperform |
| 2024-12-02 | Bestätigt | Stifel | Buy |
| 2024-09-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-23 | Eingeleitet | Stifel | Buy |
| 2023-11-21 | Fortgesetzt | Guggenheim | Buy |
| 2020-09-29 | Eingeleitet | Guggenheim | Buy |
| 2020-01-10 | Eingeleitet | Craig Hallum | Buy |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-13 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Soleno Therapeutics Inc Aktie (SLNO) Neueste Nachrichten
Soleno (SLNO) Q2 Revenue Jumps 30% - AOL.com
What is the long term forecast for Soleno Therapeutics Inc. stockInsider Accumulation Tracker - thegnnews.com
Soleno Therapeutics Inc. Chart Enters High Volatility ZoneAI Driven Buy Alert Trade Blueprint Released - metal.it
Soleno Therapeutics: Analysts Predict 43.2% Upside Potential - AInvest
How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15% - Yahoo Finance
Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going - Yahoo Finance
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results - ADVFN Brasil
Regression Model Predicts Rangebound Movement in Soleno Therapeutics Inc.High Growth Low Risk Stock Selection Gets Analyst Nod - metal.it
Soleno signals $500M cash war chest and robust Vykat XR launch trajectory while advancing EU expansion - MSN
Soleno Therapeutics Posts Strong Q2 Earnings, Expects Continued Growth Despite Challenges. - AInvest
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Q2 2025 Earnings Call Transcript - Insider Monkey
Soleno Therapeutics’ Earnings Call Highlights Success and Optimism - TipRanks
Soleno Therapeutics Receives Bullish Rating from Guggenheim, Price Target Raised to $106.00 - AInvest
Stifel raises Soleno Therapeutics stock price target to $118 on strong launch - Investing.com Nigeria
Soleno Therapeutics price target raised to $120 from $115 at TD Cowen - TipRanks
Guggenheim raises Soleno Therapeutics stock price target to $106 on strong sales By Investing.com - Investing.com South Africa
Guggenheim raises Soleno Therapeutics stock price target to $106 on strong sales - Investing.com Australia
Earnings call transcript: Soleno Therapeutics beats Q2 2025 forecasts with strong revenue - Investing.com
Soleno Therapeutics Q2 2025: Key Contradictions in Time to Fill and Revenue Growth Expectations - AInvest
Soleno Therapeutics Reports Strong Q2 2025 Performance - TipRanks
Soleno Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Transcript : Soleno Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Strong Buy Recommendation for Soleno Therapeutics Driven by Impressive Vykat XR Launch and Market Demand - TipRanks
Soleno (SLNO) Q2 Revenue Jumps 30% - The Motley Fool
SOLENO THERAPEUTICS INC SEC 10-Q Report - TradingView
Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Soleno Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Soleno Therapeutics earnings beat by $0.55, revenue topped estimates - Investing.com Canada
Soleno reports $32.7 million in Q2 revenue from VYKAT XR launch By Investing.com - Investing.com South Africa
Soleno reports $32.7 million in Q2 revenue from VYKAT XR launch - Investing.com Nigeria
Soleno Therapeutics Q2 2025 Financial Results and VYKAT XR Launch Update - TradingView
Soleno Therapeutics Q2 net loss $4.7 mln - MarketScreener
Soleno Therapeutics Provides Update on U.S. Launch of - GlobeNewswire
Earnings Flash (SLNO) Soleno Therapeutics, Inc. Reports Q2 Revenue $32.7M, vs. FactSet Est of $25.1M - MarketScreener
Soleno Therapeutics Reports Q2 2025 Financial Results, Updates on VYKAT XR Launch - AInvest
Soleno Reports First Revenue Quarter: VYKAT XR Launch Draws 295 Prescribers in 90 Days - Stock Titan
When Will Soleno Therapeutics, Inc. (NASDAQ:SLNO) Become Profitable? - 富途牛牛
Is Soleno Therapeutics Inc. a growth stock or a value stockDiscover undervalued opportunities early - Jammu Links News
When is Soleno Therapeutics Inc. stock expected to show significant growthDynamic investment opportunities - Jammu Links News
Is Soleno Therapeutics Inc. a good long term investmentCapitalize on market trends before they peak - Jammu Links News
What makes Soleno Therapeutics Inc. stock price move sharplyHigh-impact investment strategies - Jammu Links News
What are analysts’ price targets for Soleno Therapeutics Inc. in the next 12 monthsUnmatched market gains - Jammu Links News
How does Soleno Therapeutics Inc. compare to its industry peersRealize exceptional returns through smart trading - Jammu Links News
What is the risk reward ratio of investing in Soleno Therapeutics Inc. stockCapitalize on momentum-driven investment opportunities - Jammu Links News
Should I hold or sell Soleno Therapeutics Inc. stock in 2025Maximize gains with proven stock analysis - Jammu Links News
What are the latest earnings results for Soleno Therapeutics Inc.Unlock powerful portfolio management tools - Jammu Links News
How does Soleno Therapeutics Inc. generate profit in a changing economyExplosive trading growth - Jammu Links News
Soleno Therapeutics Inc. Stock Analysis and ForecastMaximize returns with expert trading insights - Jammu Links News
What catalysts could drive Soleno Therapeutics Inc. stock higher in 2025Stay ahead with daily market updates - Jammu Links News
What analysts say about Soleno Therapeutics Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What machine learning models say about Soleno Therapeutics Inc.Fast Gaining Stock Screener Reports Released - metal.it
Finanzdaten der Soleno Therapeutics Inc-Aktie (SLNO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):